SCHEMBL275596

SCHEMBL275596

Nc1ccc2c(c1)C(CO)c1cc(N)ccc1-2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 2/20 0.37
CDK5R1 Q15078 1/20 0.37
HRH3 Q9Y5N1 1/20 0.35
TSHR P16473 3/20 0.34
POLB P06746 2/20 0.34
GLA P06280 1/20 0.34
GAA P10253 1/20 0.34
NPC1 O15118 3/20 0.33
ALDH1A1 P00352 3/20 0.33
RAB9A P51151 3/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNA4 P43681 1/20 0.33
TP53 P04637 1/20 0.33
CYP3A4 P08684 1/20 0.33
MAPK1 P28482 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
PTPRC P08575 2/20 0.32
LMNA P02545 2/20 0.32
HPGD P15428 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29844446 1.00 CDK5 (0.37) CDK5CDK5R1HRH3TSHRPOLB
SCHEMBL29844508 1.00 CDK5 (0.37) CDK5CDK5R1HRH3TSHRPOLB
Hydrochloric Acid SCHEMBL27734241 0.98 CDK5 (0.36) CDK5CDK5R1HRH3TSHRPOLB
Hydrochloric Acid SCHEMBL1114916 0.98 CDK5 (0.36) CDK5CDK5R1HRH3TSHRPOLB
SCHEMBL29844647 0.91 HTR2A (0.47) CDK5CDK5R1HRH3TSHRPOLB
SCHEMBL1230997 0.91 HTR2A (0.47) CDK5CDK5R1HRH3TSHRPOLB
SCHEMBL14327287 0.89 ALDH1A1 (0.36) CDK5CDK5R1HRH3TSHRGAA
SCHEMBL12009751 0.85
SCHEMBL19682135 0.79 GAA (0.34) HRH3POLBGAAALDH1A1RAB9A
SCHEMBL12336639 0.78 ESR1 (0.37) CDK5CDK5R1TSHRPOLBGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10130720-B2 Composition comprising a polymeric reagent NEKTAR THERAPEUTICS (US) 2018-11-20 US claimed
US-20170348426-A1 COMPOSITION COMPRISING A POLYMERIC REAGENT NEKTAR THERAPEUTICS 2017-12-07 US claimed
CN-110591079-B Preparation method of monofunctional nonlinear polyethylene glycol 厦门赛诺邦格生物科技股份有限公司 2022-08-02 CN disclosed
US-20220143201-A1 COMPOSITION COMPRISING A POLYMERIC REAGENT NEKTAR THERAPEUTICS (US) 2022-05-12 US disclosed
US-20220143201-A1 COMPOSITION COMPRISING A POLYMERIC REAGENT NEKTAR THERAPEUTICS (US) 2022-05-12 US disclosed
US-11266742-B2 Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates NEKTAR THERAPEUTICS (US) 2022-03-08 US disclosed
US-20200276320-A1 COMPOSITION COMPRISING A POLYMERIC REAGENT NEKTAR THERAPEUTICS (US) 2020-09-03 US disclosed
US-20200276320-A1 COMPOSITION COMPRISING A POLYMERIC REAGENT NEKTAR THERAPEUTICS (US) 2020-09-03 US disclosed
US-10695435-B2 Composition comprising a polymeric reagent NEKTAR THERAPEUTICS (US) 2020-06-30 US disclosed
US-10695435-B2 Composition comprising a polymeric reagent NEKTAR THERAPEUTICS (US) 2020-06-30 US disclosed
CN-110591079-A Preparation method of monofunctional nonlinear polyethylene glycol 厦门赛诺邦格生物科技股份有限公司 2019-12-20 CN disclosed
EP-1896082-A2 CONJUGATES HAVING A DEGRADABLE LINKAGE AND POLYMERIC REAGENTS USEFUL IN PREPARING SUCH CONJUGATES Nektar Therapeutics AL, Corporation (US) 2008-03-12 EP disclosed
WO-2007075534-A2 POLYMER CONJUGATES OF GLP-1 NEKTAR THERAPEUTICS AL, CORPORATION (US) 2007-07-05 WO disclosed
US-20070092482-A1 Conjugates of a G-CSF moiety and a polymer NEKTAR THERAPEUTICS 2007-04-26 US disclosed
US-20070092482-A1 Conjugates of a G-CSF moiety and a polymer NEKTAR THERAPEUTICS 2007-04-26 US disclosed
US-20070092482-A1 Conjugates of a G-CSF moiety and a polymer NEKTAR THERAPEUTICS 2007-04-26 US disclosed
WO-2007019331-A2 CONJUGATES OF A G-CSF MOIETY AND A POLYMER NEKTAR THERAPEUTICS AL, CORPORATION (US) 2007-02-15 WO disclosed
WO-2007019331-A2 CONJUGATES OF A G-CSF MOIETY AND A POLYMER NEKTAR THERAPEUTICS AL, CORPORATION (US) 2007-02-15 WO disclosed
US-20060293499-A1 Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates NEKTAR THERAPEUTICS 2006-12-28 US disclosed
WO-2006138572-A2 CONJUGATES HAVING A DEGRADABLE LINKAGE AND POLYMERIC REAGENTS USEFUL IN PREPARING SUCH CONJUGATES NEKTAR THERAPEUTICS AL, CORPORATION (US) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220143201-A1 COMPOSITION COMPRISING A POLYMERIC REAGENT CD44, FCGRT, C9 CDK5 3508/4885CDK5R1 3632/4885HRH3 123/4885
US-20200276320-A1 COMPOSITION COMPRISING A POLYMERIC REAGENT CD44, FCGRT, C9 CDK5 3508/4885CDK5R1 3632/4885HRH3 123/4885
US-10130720-B2 Composition comprising a polymeric reagent CD44, FCGRT, C9 CDK5 3508/4885CDK5R1 3632/4885HRH3 123/4885
US-11266742-B2 Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates CD44, DNPEP, SI CDK5 2593/4885CDK5R1 2803/4885HRH3 260/4885
US-20070092482-A1 Conjugates of a G-CSF moiety and a polymer CSF3R, GMFG, CSF1R CDK5 4207/4885CDK5R1 4402/4885HRH3 824/4885
US-20170348426-A1 COMPOSITION COMPRISING A POLYMERIC REAGENT CD44, FCGRT, C9 CDK5 3508/4885CDK5R1 3632/4885HRH3 123/4885
US-10695435-B2 Composition comprising a polymeric reagent CD44, FCGRT, C9 CDK5 3508/4885CDK5R1 3632/4885HRH3 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.